14443-33-5

Basic information

• Product Name: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-phenyl-
• Synonyms: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-phenyl-;Nsc26289;9-Phenylguanine;2-AMino-9-phenyl-1H-purin-6(9H)-one
• CAS NO: 14443-33-5
• Molecular Formula: C₁₁H₉N₅O
• Molecular Weight: 227.22206
• Mol File: 14443-33-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 515.2 ℃at 760 mmHg
• Flash Point: 265.4 ℃
• Appearance: /
• Density: 1.58 g/cm³
• Vapor Pressure: 1E-10mmHg at 25°C
• Refractive Index: 1.804
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-phenyl-(14443-33-5)
• EPA Substance Registry System: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-phenyl-(14443-33-5)

Safety Data

• Hazardous Substances Data: 14443-33-5(Hazardous Substances Data)

Usage

General Description

6H-Purin-6-one, 2-amino-1,9-dihydro-9-phenyl- is a chemical compound that belongs to the purine group and is characterized by its molecular structure containing a purin-6-one core with an amino group at the 2-position and a phenyl group at the 9-position. It is an important intermediate in the synthesis of various pharmaceutical compounds, including antiviral and anticancer agents. 6H-Purin-6-one, 2-amino-1,9-dihydro-9-phenyl- has potential therapeutic applications and has been studied for its pharmacological properties. Additionally, it is also used as a precursor in organic synthesis for the preparation of various bioactive compounds.

InChI:InChI=1/C11H9N5O/c12-11-14-9-8(10(17)15-11)13-6-16(9)7-4-2-1-3-5-7/h1-6H,(H3,12,14,15,17)

Upstream product

• 1485770-83-9 2-N-acetyl-6-O-diphenylcarbamoyl-9-N’-phenylguanine 
• 108-86-1 bromobenzene 
• 73-40-5 2-amino-1,9-dihydro-6H-purin-6-one 
• 591-50-4 iodobenzene 
• 66950-63-8 phenyl N,N-dimethylsulfamate 
• 65009-00-9 O-phenyl N,N-diethylcarbamate 
• 108-95-2 phenol 
• 98-80-6 phenylboronic acid 
• 309947-87-3 N²,N²-bis-boc-2-amino-6-chloropurine 

Downstream Products

• 5444-47-3 9-phenyl-3,9-dihydro-purine-2,6-dione 

Relevant articles and documents

N -Arylation of (hetero)arylamines using aryl sulfamates and carbamates via C-O bond activation enabled by a reusable and durable nickel(0) catalyst

An effective and general aryl amination protocol has been developed using a magnetically recoverable Ni(0) based nanocatalyst. This new stable catalyst was prepared on Fe3O4@SiO2 modified by EDTA and investigated by FT-IR, EDX, TEM, XRD, DLS, FE-SEM, XPS, NMR, TGA, VSM, ICP and elemental analysis techniques. The reaction proceeded via carbon-oxygen bond cleavage of (hetero)aryl carbamates and sulfamates under simple and mild conditions without the use of any external ligands. This method demonstrated functional group tolerance in the N-arylation of various nitrogen-containing compounds as well as aliphatic amines, anilines, pyrroles, pyrazoles, imidazoles, indoles, and indazoles with good to excellent yields. Furthermore, the catalyst could be easily recovered by using an external magnetic field and directly reused at least six times without notable reduction in its activity. This journal is

New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain

The heterotrimeric influenza virus polymerase performs replication and transcription of viral RNA in the nucleus of infected cells. Transcription by "cap-snatching" requires that host-cell pre-mRNAs are bound via their 5′ cap to the PB2 subunit. Thus, the PB2 cap-binding site is potentially a good target for new antiviral drugs that will directly inhibit viral replication. Docking studies using the structure of the PB2 cap-binding domain suggested that 7-alkylguanine derivatives substituted at position N-9 and N-2 could be good candidates. Four series of 7,9-di- and 2,7,9-trialkyl guanine derivatives were synthesized and evaluated by an AlphaScreen assay in competition with a biotinylated cap analogue. Three synthesized compounds display potent in vitro activity with IC50 values lower than 10 μM. High-resolution X-ray structures of three inhibitors in complex with the H5N1 PB2 cap-binding domain confirmed the binding mode and provide detailed information for further compound optimization.